Vaccination to Prevent Herpes Zoster in Older Adults

Journal of Pain

Volumn 9, Issue 1 SUPPL., 2008, Pages 31-36

  Gnann Jr , John W ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Herpes zoster; postherpetic neuralgia; zoster vaccine

Indexed keywords

PLACEBO; VARICELLA ZOSTER VACCINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE WARMTH; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; POSTHERPETIC NEURALGIA; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VARICELLA ZOSTER VIRUS;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; GERIATRICS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 37349030376     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2007.10.007     Document Type: Article

References (33)

1. Arvin A.M. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 166 Suppl 1 (1992) S35-S41
2. Asanuma H., Sharp M., Maecker H.T., Maino V.C., and Arvin A.M. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 181 (2000) 859-866
3. Berger R., Florent G., and Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immunol 32 (1981) 24-27
4. Buchbinder S.P., Katz M.H., Hessol N.A., Lin J.Y., O'Malley P.M., Underwood R., and Holberg S.D. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 166 (1992) 1153-1156
5. Burke B.L., Steele R.W., Beard O.W., Wood J.S., Cain T.D., and Marmor D.J. Immune response to varicella-zoster in the aged. Arch Intern Med 142 (1982) 291-293
6. Centers for Disease Control and Prevention: General recommendations on immunization: Recommendations and reports. Morb Mortal Weekly Rep 55(RR-15):1-48, Dec 1, 2006
7. Centers for Disease Control and Prevention: Recommended Adult Immunization Schedule-United States, October 2007-September 2008. Morb Mortal Weekly Rep 56:Q1-Q4, 2007
8. Coplan P.M., Schmader K., Nikas A., Chan I.S., Choo P., Levin M.J., Johnson G., Bauer M., Williams H.M., Kaplan K.M., Guess H.A., and Oxman M.N. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. J Pain 5 (2004) 344-356
9. Dolin R., Reichman R.C., Mazur M.H., and Whitley R.F. Herpes zoster-varicella infections in immunocompromised patients. Ann Intern Med 89 (1978) 375-388
10. Donahue J.G., Choo P.W., Manson J.E., and Plat R. The incidence of herpes zoster. Arch Intern Med 155 (1995) 1605-1609
11. Gnann Jr. J.W., and Whitley R.J. Clinical practice: Herpes zoster. N Engl J Med 347 (2002) 340-346
12. Hayward A.R., and Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 7 (1987) 174-178
13. Itzler RF, Pellissier JM, Davies G, Carides G, Cook JR, Schmader K: Zostavax reduces health care encounters for herpes zoster (abstract 860). Proceedings of the 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, October 12-15, 2006
14. Kerzner B., Murray A.V., Cheng E., Ifle R., Harvey P.R., Tomlinson M., Barben J.L., Rarrick K., Stek J.E., Chung M.O., Schödel F.P., Wang W.W., Xu J., Chan I.S., Silber J.L., and Schlienger K. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 55 (2007) 1499-1507
15. Kilgore P.E., Kruszon-Moran D., Seward J.F., Jumaan A., Van Loon F.P.L., Forghani B., McQuillian G.M., Wharton M., Fehrs L.J., Cossen C.K., and Hadler S.C. Varicella in Americans from NHANES III: Implications for control through routine immunization. J Med Virol 70 Suppl 1 (2003) S111-S118
16. Kimberlin D.W., and Whitley R.J. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 356 (2007) 1338-1343
17. Levin M.J., Barber D., Goldblatt E., Jones M., LaFleur B., Chan C., Stinson D., Zerbe G.O., and Hayward A.R. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: Duration of booster effect. J Infect Dis 178 Suppl 1 (1998) S109-S112
18. Levin M.J., Murray M., Rotbart H.A., Zerbe G.O., White C.J., and Hayward A.R. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 166 (1992) 253-259
19. Levin M.J., Smith J.G., Kaufhold R.M., Barber D., Hayward A.R., Chan C.Y., Chan I.S., Li D.J., Wang W., Keller P.M., Shaw A., Silber J.L., Schlienger K., Chalikonda I., Vessey S.J., and Caulfield M.J. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188 (2003) 1336-1344
20. Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 61 (2001) 187-196
21. Macalalad M., Marcano T., Guzman M., Moya J., Jurado F., Thompson M., Meechan C., Li D., Schliefer K., Chan I., Sadoff J., Schodel F., and Silber J.L. Safety and immunogenecity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 25 (2007) 2139-2144
22. Merck & Co., Inc.: Zoster vaccine live (Oka/Merck) Zostavax Package Insert. http://www.fda/gov/cber/label/zosmer052506LB.htm. Accessed October 1, 2007
23. Miller A.E. Selective decline in cellular immune responses to varicella-zoster in the elderly. Neurology 30 (1980) 582-587
24. Oxman M.N. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45 (1995) S41-S46
25. Oxman MN, Levin MJ, Johnson G, Zhang J, Caulfield MJ: The effect of age on clinical and immunologic responses to a herpes zoster vaccine (abstract 858). Proceedings of the 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, October 12-15, 2006
26. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., Arbeit R.D., Simberkoff M.S., Gershon A.A., Davis L.E., Weinberg A., Boardman K.D., Williams H.M., Zhang J.H., Peduzzi P.N., Beisel C.E., Morrison V.A., Guatelli J.C., Brooks P.A., Kauffman C.A., Pachucki C.T., Neuzil K.M., Betts R.F., Wright P.F., Griffin M.R., Brunell P., Soto N.E., Marques A.R., Keay S.K., Goodman R.P., Cotton D.J., Gnann Jr. J.W., Loutit J., Holodniy M., Keitel W.A., Crawford G.E., Yeh S.S., Lobo Z., Toney J.F., Greenberg R.N., Keller P.M., Harbecke R., Hayward A.R., Irwin M.R., Kyriakides T.C., Chan C.Y., Chan I.S., Wang W.W., Annunziato P.W., and Silber J.L. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
27. Oxman MN, Weinberg A, Stanley HA, Johnson GR, Levin MJ, Zhang JH, Caulfield MJ, Hayward AR, Irwin MR, Chan ISF, Clair J, Smith JG, The Shingles Prevention Study Group: VZV-specific immune responses in older adult recipients of a clinically effective herpes zoster vaccine (abstract PP193): Proceedings of the European Union Geriatric Medicine Society, 4th Congress, Geneva, Switzerland, August 23-26, 2006. J Nutr Health Aging 10:39, 2006
28. Oxman MN, Williams HM, Levin MJ, Johnson GR, Zhang JH, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Annunziato PW, Chan ISF, Silber JL, Wang WWB: Efficacy of zoster vaccine according to dermatome region (abstract 2699). Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 15-18, 2005
29. Ragozzino M.W., Melton L.J.I., Kurland L.T., Chu C.P., and Perry H.O. Populations-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61 (1982) 310-316
30. Schmader K, Saddier P, Johnson G, Wang W, Zhang J, Chan ISF, Levin MJ, Oxman MN: The effect of zoster vaccine on interference of herpes zoster with activities of daily living (abstract 859). Proceedings of the 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Canada, October 12-15, 2006
31. Sutradhar SC, Wang WWB, Schlienger K, Stek JE, Xu J, Chan ISF, Silber JL: Comparison of immunogenicity and safety of Zostavax in adults 50 to 59 years old and those > 60 years old (abstract S27). Proceedings of the NFID Tenth Annual Conference on Vaccine Research, Baltimore, MD, April 30-May 2, 2007
32. Trannoy E., Berger R., Hollander G., Bailleux F., Heimendinger P., Vuillier D., and Creusvaux H. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: A randomized, controlled, dose-response trial. Vaccine 18 (2000) 1700-1706
33. Tyring S.K., Diaz-Mitoma F., Padget L.G., Nunez M., Poland G., Cassidy W.M., Bundick N.D., Li J., Chan I.S., Stek J.E., and Annunziato P.W. Safety and tolerability of a high-potency zoster vaccine in adults >50 or years of age. Vaccine 25 (2007) 1877-1883